Skip to main content
. 2021 Nov 22;11(11):1239. doi: 10.3390/jpm11111239

Figure 1.

Figure 1

Provides an overview of how molecular classification can guide a personalized approach to PPGL patients. PARP: poly-(ADP)-ribose polymerase, mTOR: mechanistic Target of Rapamycin, MEK: mitogen-activated protein kinase kinase (MAP2K), TK: tyrosine kinase, MIBG: metaiodobenzylguanidine, PRRT: peptide receptor radionuclide therapy, SST: somatostatin.